Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple hormone dose shift boost embryo quality in older IVF patients?

NCT ID NCT07691073

Disease control Sponsor: Fundacion Dexeus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial tests two different daily doses of fertility hormones (follitropin-delta and menotropin) during ovarian stimulation for IVF in women aged 35 and older. The goal is to see which dosing strategy leads to more good-quality embryos. The study involves 240 women with normal ovarian reserve and no severe male infertility factors. Results may help personalize IVF treatment for older women.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
follitropin-delta (Rekovelle) and menotropin (Menopur)
What this could lead to
If one dosing strategy clearly produces more good-quality embryos, it could help older women undergoing IVF have a better chance of a successful pregnancy.
What could go wrong
This is a mid-stage trial with 240 participants, so results may not apply to all women. The study focuses on embryo quality, not live birth rates, so even a positive finding may not guarantee a baby.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

38 to 41 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Undergoing preimplantation genetic screening cycles * AMH 0.5 - 3.5 ng/ml or AFC 5-20 (results of up to one year will be valid) * BMI 18.5 - 30 Kg/m2 * Normal karyotypes in both partners Exclusion Criteria: * Previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol), according to Bologna criteria * Severe male factor requiring TESE (testicular sperm extraction) * Administration of any other drug potentially interfering with the treatment * Contraindication for hormonal treatment * Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfere with the trial assessment) * Monogenic disease to be detected with PGT-M * Biochemical and/or ultrasonographic evidence of polycystic ovarian syndrome * Endocrinological and/or autoimmune disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus

    Barcelona, 08037, Spain

  • Dexeus Mujer Sabadell

    Sabadell, Barcelona, 08203, Spain

  • Dexeus Mujer Sant Cugat

    Sant Cugat del Vallès, Barcelona, 08195, Spain

  • Dexeus Mujer Tarragona

    Tarragona, 43206, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.